59
Participants
Start Date
May 17, 2021
Primary Completion Date
September 19, 2022
Study Completion Date
September 19, 2022
Solriamfetol
Solriamfetol 75 mg/d Solriamfetol 150 mg/d
Placebo
Placebo
IRCCS Ospedale San Raffaele - Servizio Farmacia, Milan
The Center for Sleep & Wake Disorders, Chevy Chase
Instiut de Reccerca Biomedica de Lledia, Lleida
Advanced Respiratory and Sleep Medicine, PLLC, Huntersville
Bogan Sleep Consultants, LLC, Columbia
NeuroTrials Research Inc, Atlanta
The Neurological Center of north Georgia., Gainesville
Clinical Neuroscience Solutions, Inc, Jacksonville
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna
CTI-Clinical Research Center, Cincinnati
Intrepid Research, LLC, Cincinnati
Henry Ford Health System, Novi
UOC Farmacia e Politiche del farmaco, edif 41, Pisa
Sleep Medicine & Research Center, Chesterfield
Sleep Therapy & Research Center, San Antonio
FutureSearch Trials of Neuroglogy, Austin
Southern California Institute for Respiratory Disease, Los Angeles
SDS Clinical Trials, Inc, Santa Ana
IRCCS Associazione Oasi Maria SS Onlus, Troina
Sleep and Performance Research Center, Spokane
University of Calgary, Calgary
MedSleep Inc. o/a Toronto Sleep Institute, Toronto
Jodha Tishon Inc, Toronto
Amphia Hospital, Breda
Sleep-Waakcentrum SEIN, Heemstede
Hospital Clinic de Barcelona, Barcelona
Hospital de la Santa Creu I Sant Pau, Barcelona
Royal Papworh Hospital, Cambridge
Lead Sponsor
Axsome Therapeutics, Inc.
INDUSTRY